Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
AIMM Therapeutics B.V. - Product Pipeline Review - 2016 Summary
Global Markets Direct's, 'AIMM Therapeutics B.V. - Product Pipeline Review - 2016', provides an overview of the AIMM Therapeutics B.V.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by AIMM Therapeutics B.V., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of AIMM Therapeutics B.V. - The report provides overview of AIMM Therapeutics B.V. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses AIMM Therapeutics B.V.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features AIMM Therapeutics B.V.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy
- Evaluate AIMM Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for AIMM Therapeutics B.V. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding AIMM Therapeutics B.V.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 AIMM Therapeutics B.V. Snapshot 6 AIMM Therapeutics B.V. Overview 6 Key Information 6 Key Facts 6 AIMM Therapeutics B.V. - Research and Development Overview 7 Key Therapeutic Areas 7 AIMM Therapeutics B.V. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 AIMM Therapeutics B.V. - Pipeline Products Glance 14 AIMM Therapeutics B.V. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 AIMM Therapeutics B.V. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 AIMM Therapeutics B.V. - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 AIMM Therapeutics B.V. - Drug Profiles 18 CR-8020 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody for Acute Myelocytic Leukemia 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody for Colon Carcinoma 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody for Cytomegalovirus Infections 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody for Hepatitis C Infection 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody for Human Rhinovirus Infections 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody for Melanoma 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody for MRSA Infections 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibody for Multiple Myeloma 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibody for Oncology 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibody for Pancreatic Cancer 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AM-18 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AM-28 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Monoclonal Antibody for Clostridium Difficile Infections 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibodies for Hepatitis B Infection 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 AIMM Therapeutics B.V. - Pipeline Analysis 35 AIMM Therapeutics B.V. - Pipeline Products by Target 35 AIMM Therapeutics B.V. - Pipeline Products by Route of Administration 36 AIMM Therapeutics B.V. - Pipeline Products by Molecule Type 37 AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action 38 AIMM Therapeutics B.V. - Locations And Subsidiaries 39 Head Office 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
AIMM Therapeutics B.V., Key Information 6 AIMM Therapeutics B.V., Key Facts 6 AIMM Therapeutics B.V. - Pipeline by Indication, 2016 8 AIMM Therapeutics B.V. - Pipeline by Stage of Development, 2016 10 AIMM Therapeutics B.V. - Monotherapy Products in Pipeline, 2016 11 AIMM Therapeutics B.V. - Out-Licensed Products in Pipeline, 2016 12 AIMM Therapeutics B.V. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 AIMM Therapeutics B.V. - Phase II, 2016 14 AIMM Therapeutics B.V. - Preclinical, 2016 15 AIMM Therapeutics B.V. - Discovery, 2016 16 AIMM Therapeutics B.V. - Unknown, 2016 17 AIMM Therapeutics B.V. - Pipeline by Target, 2016 35 AIMM Therapeutics B.V. - Pipeline by Route of Administration, 2016 36 AIMM Therapeutics B.V. - Pipeline by Molecule Type, 2016 37 AIMM Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2016 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.